The taxonomic range for the selected organisms is: Mycobacterium tuberculosis The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea
docking studies with the substrate 1-oleoyl-glycerol in the form of the tetrahedral reaction intermediate. In the best-docking mode, the polar glycerol moiety of the substrate is in direct interaction with catalytically important residues Ser110, His256, Glu257, Met111 and Leu39 from the core region and Tyr181 situated within helix 3 of the cap. No positional preference for sn-1(3) or 2-MGs has been reported for any MGL
docking studies with the substrate 1-oleoyl-glycerol in the form of the tetrahedral reaction intermediate. In the best-docking mode, the polar glycerol moiety of the substrate is in direct interaction with catalytically important residues Ser110, His256, Glu257, Met111 and Leu39 from the core region and Tyr181 situated within helix 3 of the cap. No positional preference for sn-1(3) or 2-MGs has been reported for any MGL
substrate specificity, the enzyme hydrolyses monoacylglycerol substrates, both long chain di- and triacylglycerols, although the turnover is lower than with monoacylglycerol, overview, no activity of the recombinant enzyme with lysophospholipid substrates, recombinant Rv0183 hydrolyses synthetic vinyl esters with various acyl chain lengths, chain length dependence, overview
Mycobacterium tuberculosis MGL cannot be inhibited with JZL-184, a known inhibitor of human MGL. Differences in the binding pocket of mtbMGL compared to human MGL impair JZL-184 inhibition, overview. The human enzyme has an amphipathic cap helix 1 whereas cap helix1 of mtbMGL is mostly hydrophobic. Structure-based analysis for potential inhibitors for mtbMGL. JZL-184 docking study, overview
Mycobacterium tuberculosis MGL cannot be inhibited with JZL-184, a known inhibitor of human MGL. Differences in the binding pocket of mtbMGL compared to human MGL impair JZL-184 inhibition, overview. The human enzyme has an amphipathic cap helix 1 whereas cap helix1 of mtbMGL is mostly hydrophobic. Structure-based analysis for potential inhibitors for mtbMGL. JZL-184 docking study, overview
docking studies and structure comparison with the human enzyme, overview. The structure reveals remarkable similarities with MGL from humans (hMGL) in both, the cap region and the alpha/beta core
docking studies and structure comparison with the human enzyme, overview. The structure reveals remarkable similarities with MGL from humans (hMGL) in both, the cap region and the alpha/beta core
docking studies revealing numerous interactions of mtbMGL to recognize polar and apolar segments of the monoacylglycerol target substrate, and structure comparison with the human enzyme, overview. The three-dimensional structure of mtbMGL reveals an alpha/beta hydrolase fold with an open cap conformation
docking studies revealing numerous interactions of mtbMGL to recognize polar and apolar segments of the monoacylglycerol target substrate, and structure comparison with the human enzyme, overview. The three-dimensional structure of mtbMGL reveals an alpha/beta hydrolase fold with an open cap conformation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
enzyme mtbMGL in open conformation, sitting drop vapor diffusion method and microseeding, mixing 500 nl of 10 mg/ml protein solution with 500 nl of crystallization solution containing 0.1 M carboxylic acids, 0.1 M sodium HEPES/MOPS, pH 7.5, 20% ethylene glycol, and 10% PEG 8000, 4 months, 20°C, microseeding by mixing of 400 nl protein solution with 400 nl crystallization solution and 200 nl seeding stock, containing 0.03 M NaNO3, 0.03 M Na2HPO4, 0.03 M (NH4)2SO4, 0.1 M Na HEPES/MOPS, pH 7.8, 12% MPD, 12% PEG 1000 and 12% PEG 3350, 2 weeks, 20°C, X-ray diffraction structure determination and analysis at 1.80 A resolution, molecular replacement using the PDB IDs 3PE6 and 1W53 as search templates
Differences in the binding pocket of mtbMGL compared to human MGL open the possibility for specific inhibition of MGL from the pathogen Mycobacterium tuberculosis and use in the human pathogen treatment